Please use this identifier to cite or link to this item: http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2045
Title: Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
Authors: Urueña, Analía
Micone, Paula
Magneres, María Cecilia
Mould-Quevedo, Joaquín
Giglio, Norberto
Keywords: Influenza
Vacunas
Costo efectividad
Vacuna Trivalente contra la Influenza
Vacuna Cuadrivalente contra la Influenza
Issue Date: 2022
Citation: Urueña A, Micone P, Magneres C, Mould-Quevedo J, Giglio N. Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina. Vaccines. 2021; 9(4):335. https://doi.org/10.3390/vaccines9040335
Abstract: The burden of seasonal influenza disease in Argentina is considerable. The cost-effectiveness of trivalent (TIV) versus quadrivalent influenza vaccine (QIV) in Argentina was assessed. An age-stratified, static, decision-tree model compared the costs and benefits of vaccination for an average influenza season. Main outcomes included: numbers of influenza cases; general practitioner (GP) visits; complicated ambulatory cases; hospitalizations; deaths averted; and costs per quality-adjusted life years (QALYs) gained. Epidemiological data from Argentina for 2014–2019 were used to determine the proportion of A and B strain cases, and the frequency of mismatch between vaccine and circulating B strains. To manage uncertainty, one-way and probabilistic sensitivity analyses were performed. Switching from TIV to QIV would prevent 19,128 influenza cases, 16,164 GP visits, 2440 complicated ambulatory cases, 524 hospitalizations, and 82 deaths. Incremental cost–effectiveness ratios (ICERs) per QALY were 13,590 and 11,678 USD from the payer’s and societal perspectives, respectively. The greatest health benefits and direct medical cost savings would occur in ≥ 65-year-olds. One-way sensitivity analyses demonstrated the principal drivers of ICER to be vaccine acquisition costs, environmental B strain predominance, and B strain mismatch. Introducing QIV in Argentina would be beneficial and cost-effective relative to TIV, particularly in older adults.
URI: https://doi.org/10.3390/vaccines9040335
http://repositorio.isalud.edu.ar/xmlui/handle/123456789/2045
Appears in Collections:Trabajos Publicados

Files in This Item:
File Description SizeFormat 
Urueña. Vaccines-9(4).pdf2,76 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.